XIENCE V Official Site

SPIRIT IV 1-Year Results

SPIRIT III 3-Year Results

SPIRIT II & III Meta-Analysis 2-Year Results

SPIRIT V 1-Year Results

Learn about the benefits of proven design

* XIENCE V has demonstrated statistical superiority in the primary endpoints of SPIRIT IV, SPIRIT III and SPIRIT II in target lesion failure, in-segment late loss and in-stent late loss respectively. Source: SPIRIT IV 1-year results, Gregg Stone, TCT 2009 and XIENCE V IFU. TAXUS Express was the control in SPIRIT IV.

References

XIENCE V IFU.
XIENCE V IFU.
Source: SPIRIT IV 1-Year results, Gregg Stone, TCT 2009.

Control stents: SPIRIT II (TAXUS Express 73% of lesions, TAXUS Liberte 27% of lesions), SPIRIT III (TAXUS Express), SPIRIT IV (TAXUS Express)

AP2931122 Rev. A

Site Map | International Terms of Use | International Privacy Policy | Contact Us

All illustrations are artist’s renditions.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.